Genomic Health, Inc. (NASDAQ:GHDX)

CAPS Rating: 4 out of 5

A life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.

Results 1 - 20 of 41 : 1 2 3 Next »

Recs

0
Member Avatar wmansvelt (30.93) Submitted: 12/21/2015 2:59:18 PM : Outperform Start Price: $34.24 GHDX Score: -14.21

Long term trend will require more and more use of DNA or genomic assessments.

Recs

0
Member Avatar Tophinater (< 20) Submitted: 9/19/2014 12:01:12 AM : Outperform Start Price: $29.08 GHDX Score: -0.05

I don't know.

Recs

0
Member Avatar PatientJC (36.44) Submitted: 2/10/2014 11:40:55 AM : Outperform Start Price: $26.38 GHDX Score: -1.83

Superior fundamentals

Recs

0
Member Avatar legofkan1 (< 20) Submitted: 11/9/2013 11:07:35 AM : Outperform Start Price: $34.98 GHDX Score: -28.21

EXPANDING!

Recs

0
Member Avatar iksnamyzs (61.31) Submitted: 1/6/2013 1:10:27 PM : Outperform Start Price: $27.75 GHDX Score: -30.74

guy on dip

Recs

1
Member Avatar FoolishDane (< 20) Submitted: 11/20/2012 9:27:36 AM : Outperform Start Price: $26.83 GHDX Score: -33.78

A single treatment won't work for everyone, so there's definite promise in a company working to perfect tests so that individualized treatments may be prescribed. This would result in less frustration for the patient and his/her family and, hopefully, better survival rates.

Recs

0
Member Avatar TMFHumbleServant (81.36) Submitted: 11/20/2012 7:38:03 AM : Outperform Start Price: $26.83 GHDX Score: -33.78

Genomics will continue to play a bigger role in the future of medicine and treatments.

Recs

0
Member Avatar TMFPoinkie (97.37) Submitted: 11/7/2012 11:45:04 AM : Outperform Start Price: $28.61 GHDX Score: -39.07

Strong insider buys & strength of colon/protate cancer tests could eliminate chemo. Long

Recs

0
Member Avatar clymerjones (50.79) Submitted: 9/5/2012 10:47:49 PM : Outperform Start Price: $35.36 GHDX Score: -55.13

There is no more important health issue than getting treatments right in the fight against cancer and GHDX has the best if those tools right now. I expect their research to continue and that should them keep them in a leadership position.

Recs

0
Member Avatar TMFBoiseKen (93.06) Submitted: 7/3/2012 12:49:33 PM : Outperform Start Price: $35.86 GHDX Score: -60.52

I'd love to get it a little cheaper, but I think it can outperform over 5-10 years from here.

Recs

0
Member Avatar pthammond (21.81) Submitted: 6/15/2010 6:59:21 PM : Outperform Start Price: $14.38 GHDX Score: +19.53

A whole new way to diagnose that has to catch on. With limited competition, this company will do well.

Recs

1
Member Avatar gt1135 (21.13) Submitted: 2/10/2010 9:49:51 AM : Outperform Start Price: $16.95 GHDX Score: -15.15

Sitting near 52 week low. It won't last. Wish I had more real $$ to invest in this one at the moment.

Recs

1
Member Avatar simonhs (< 20) Submitted: 2/9/2010 7:28:05 PM : Outperform Start Price: $17.09 GHDX Score: -16.72

Aging population, more and more cancer. Might as well make some money off it.

Recs

1
Member Avatar scoobamang (< 20) Submitted: 11/25/2009 10:52:00 PM : Outperform Start Price: $18.80 GHDX Score: -28.79

Revenue increasing at a very nice clip, about to climb out of the red and into profitability, nice cash cushion. Life science sounds sexy.

Recs

1
Member Avatar neilphipps (< 20) Submitted: 6/23/2009 4:31:02 PM : Outperform Start Price: $16.48 GHDX Score: -45.35

Genomics is a promising direction for genetic studies.

Recs

1
Member Avatar Cab53RobertMsnG (85.25) Submitted: 5/28/2009 2:12:13 PM : Outperform Start Price: $19.05 GHDX Score: -65.80

GHDX

Recs

1
Member Avatar jajex1 (36.09) Submitted: 5/12/2009 9:52:38 AM : Outperform Start Price: $19.66 GHDX Score: -69.70

fransgeraedts pick

Recs

1
Member Avatar SmallPimpin (53.00) Submitted: 5/6/2009 8:14:03 PM : Outperform Start Price: $19.60 GHDX Score: -64.95

Mmm...medical tests...

Recs

1
Member Avatar jdwoollard (< 20) Submitted: 10/13/2008 6:12:51 PM : Outperform Start Price: $21.00 GHDX Score: -54.30

This company allows for targeted treatment of breast cancer. By better determining patients that will benefit from chemotherapy, there are substantial benefits for the patient and for the payors.

Recs

3
Member Avatar WindRules (< 20) Submitted: 8/16/2008 2:32:28 PM : Outperform Start Price: $23.97 GHDX Score: -35.11

This spring they got clinical validation, they received insurance approval for the Oncotype Dx test for estrogen receptor positive breast cancer. They test the DNA of the tumor against the DNA of the person who had the tumor and this gives a personalized predictor of the odds of that same cancer recurring in that person. They also test chemo therapies against and make recommendations. This is far better than population statistics, and the fact that they have insurance approval for the test means increased income. I gather that the test for progesterone receptor positive tumors is close to approval.

I spoke to a member of the board of trustees of BC/BS and he was pleased that it had been used on me. This was within 3 months of approval. It has saved me from months of chemo and radiation. It saves the insurance companies all of that money that would have been spent on my care.

With a PE ratio of 2.83, this seems a go to me.

Results 1 - 20 of 41 : 1 2 3 Next »

Featured Broker Partners